查看购物车
  • Traditional Chinese
  • English
  • Japanese
  • Korean
封面
市场调查报告书
商品编码
2011296

基因治疗市场：按载体类型、治疗方法、目标基因组、递送方法、给药途径、患者群体、治疗领域和最终用户划分－全球市场预测（2026-2032 年）

Gene Therapy Market by Vector Type, Treatment Modality, Target Genome, Delivery Mode, Route of Administration, Patient Type, Therapeutic Area, End-User - Global Forecast 2026-2032
出版日期: | 出版商: 360iResearch | 英文 199 Pages | 商品交期: 最快1-2个工作天内

价格

※ 本网页内容可能与最新版本有所差异。详细情况请与我们联繫。

预计到 2025 年，基因治疗市场价值将达到 129.1 亿美元，到 2026 年将成长到 163.5 亿美元，到 2032 年将达到 759.2 亿美元，复合年增长率为 28.80%。

主要市场统计数据
基准年 2025 129.1亿美元
预计年份：2026年 163.5亿美元
预测年份 2032 759.2亿美元
复合年增长率 (%) 28.80%

本文概述了基因疗法的发展历程，从实验阶段的突破性成果到所有相关人员对综合开发和商业化的需求。

基因治疗领域已从概念验证阶段发展成为一个成熟的生态系统，临床疗效、监管政策的明确性以及生产规模的扩大共同塑造了其商业化路径。载体工程和基因编辑平台的持续科学突破，以及对长期安全性特征的深入理解，拓展了可治疗疾病的范围，并提高了投资者和支付方的兴趣。因此，目前的策略重点不仅包括加速临床应用，还包括确保稳健的供应链、标准化的分析方法以及支援可重复商业化的永续生产模式。

识别同时发生的技术、製造、监管和支付方方面的变化，这些变化正在重新定义基因治疗的发展重点和商业性可行性。

基因治疗领域的格局正受到多项变革性变化的影响，这些变化并行发展并相互促进。首先，平台多样化正在加速。载体技术和基因组调控方法日益专业化，使得治疗方法能够更好地针对疾病和患者亚群的生物学特征进行客製化。这种技术多样化正在推动开发平臺的重组，早期专案现在更加註重载体优化、有效载荷设计和可製造性三者同时进行，而不是按顺序进行。

本检验了2025 年美国关税调整将如何加剧基因治疗产业的供应风险、重组筹资策略并加速区域製造业投资。

美国2025年实施的关税调整和贸易政策转变，为基因治疗生态系统中的企业带来了新的成本和物流方面的挑战。由于零件、试剂和专用设备需要以成本敏感的方式跨境运输，这些政策调整进一步凸显了地理分散的供应链和製造地的重要性。各公司正在重新审视筹资策略和库存政策，以便在不影响临床试验进度的前提下，自行承担或转嫁额外的进口关税。

这项研究揭示了载体选择、治疗方法、目标基因组、递送方式、患者人口统计特征、治疗重点和最终用户角色如何全面地塑造策略发展选择。

细分市场层面的趋势揭示了不同的研发路径和营运需求，这些因素对临床策略和商业化准备有重大影响。按载体类型分析显示，非病毒平台和病毒平台之间存在显着差异。虽然脂质体转染和质体DNA等非病毒方法在剂量控制和生产规模化方面通常具有优势，腺结合病毒载体、腺病毒载体、单纯疱疹病毒载体和逆转录病毒载体等病毒平台因其递送效率和组织亲和性而持续吸引临床关注。这些关键差异会影响疗效检测方法开发、批次放行标准和低温运输物流等方面的优先事项。

本文说明了美洲、欧洲、中东和非洲以及亚太地区的监管、临床和製造环境如何影响战略市场进入和营运决策。

区域趋势对监管方式、临床试验生态系统、生产投资和伙伴关係模式都有显着影响。在美洲，强大的创新生态系统和活跃的资本市场为快速的临床应用和多产品上市提供了支持。然而，该地区也面临生产需求集中的挑战，促使企业进行策略性投资，以扩大产能并增强供应链韧性。该地区的临床网络与支付方之间的合作对于证据产生和报销方案试验日益重要，并影响新型治疗方法的商业化策略。

这凸显了策略伙伴关係、製造专业化和能力投资如何重新定义主要企业的竞争定位和发展路径。

基因治疗生态系统中的企业发展趋势表明，各企业正着力于策略联盟、尽可能实现垂直整合，以及透过专业化解决载体生产和分析开发等瓶颈问题。生物技术开发公司正日益与合约开发和生产组织（CDMO）建立长期合作关係，以确保产能并共同投资于製程改进，从而降低单位成本并提高产品一致性。同时，大型製药企业正在收购和授权平台技术，以拓展其治疗产品线，并将与临床开发和商业分销相关的特定能力纳入公司内部。

为了将基因治疗创新转化为永续的市场成功，应优先考虑一体化生产、支付方合作、产品设计、区域运作和跨部门管治。

产业领导者应采取果断行动，聚焦高影响力优先事项，将科学研究潜力转化为永续的商业性成功。首先，透过策略伙伴关係和选择性内部研发，投资扩充性、柔软性的生产能力，进而降低专案风险，并实现更可预测的市场上市计画。此类投资应着重于提升分析的严谨性、流程控制和供应链的多样性，以应对可能出现的单点故障，并促进与监管机构的协调。

一种透明、多方面的调查方法，整合了专家访谈、科学文献、监管指导和供应链分析，以产生可操作的见解。

本执行摘要的研究途径结合了公开的科学文献、监管指南和行业资讯披露，并结合了对研发、生产、监管和商业战略领域专家的访谈，从中获得了定性见解。主要资讯来源包括与研发人员、第三方製造商、临床研究人员和支付方顾问的对话，这些对话揭示了正式出版物中未必总是显而易见的实际限制和战略应对措施。辅助研究则着重于同侪审查的研究、监管公告和技术白皮书，以支持有关机制和技术的论点。

本文总结了科学进步、营运准备和支付方/监管机构的期望如何相互交织，从而决定哪些基因治疗计画将产生持久的临床和商业性影响。

基因疗法正处于科学成熟度和商业性复杂性交彙的十字路口。载体工程、基因组调控技术和临床经验的进步拓宽了治疗领域，但成功越来越依赖生产、分析和供应链管理等各环节的卓越营运。监管机构和支付方不断提高预期，迫使研发人员将临床试验设计和证据计划与证明长期安全性和价值这一基本要求相一致。这些因素共同凸显了製定综合战略规划的重要性，该规划需要预见生产限制、区域监管差异以及与支付方的谈判。

目录

第一章 引言

第二章 分析方法

  • 分析设计
  • 分析框架
  • 市场规模预测
  • 数据三角测量
  • 分析结果
  • 分析的前提条件
  • 分析的局限性

第三章执行摘要

  • 首席体验长的观点
  • 市场规模和成长趋势
  • 市占率分析（2025 年）
  • FPNV定位矩阵（2025）
  • 新的商机
  • 下一代经营模式
  • 产业蓝图

第四章 市场概览

  • 产业生态系与价值链分析
  • 波特五力分析
  • PESTEL 分析
  • 市场展望
  • 市场进入（GTM）策略

第五章 市场洞察

  • 消费者分析与最终用户观点
  • 消费者体验基准测试
  • 机会映射
  • 分销通路分析
  • 价格趋势分析
  • 监理合规和标准框架
  • ESG与永续性分析
  • 中断和风险情景
  • 成本效益分析（ROI）和成本效益分析（CBA）

第六章：美国关税的累积影响（2025 年）

第七章：人工智慧（AI）的累积影响（2025 年）

第八章 基因治疗市场：依载体类型划分

  • 非病毒载体
    • 脂质体
    • 质体DNA
  • 病毒载体
    • 腺结合病毒（AAV）载体
    • 腺病毒载体
    • 单纯疱疹病毒（HSV）载体
    • 逆转录病毒载体

第九章 基因治疗市场：依治疗方法

  • 生殖细胞疗法
  • 体细胞疗法
    • 基因增强疗法
    • 基因抑制疗法

第十章 基因治疗市场：以标靶基因组划分

  • DNA修饰
  • RNA修饰

第十一章 基因治疗市场：依给药方式划分

  • Ex Vivo
  • In vivo

第十二章 基因治疗市场：依给药途径划分

  • 肌肉内部
  • 眼
  • 静脉

第十三章 基因治疗市场：依患者群体划分

  • 成年患者
  • 儿童患者

第十四章 基因治疗市场：依治疗领域划分

  • 心血管疾病
    • 冠状动脉疾病
    • 心臟衰竭
  • 感染疾病
    • B型肝炎
    • HIV
  • 单基因疾病
    • 囊肿纤维化
    • 血友病
    • 镰状细胞贫血症
  • 肿瘤性疾病
    • 骨髓恶性肿瘤
    • 固体癌

第十五章 基因治疗市场：依最终用户划分

  • CRO（委外研发机构）
  • 医院和诊所
  • 製药和生物技术公司
  • 研究机构

第十六章 基因治疗市场：依地区划分

  • 北美洲和南美洲
    • 北美洲
    • 拉丁美洲
  • 欧洲、中东和非洲
    • 欧洲
    • 中东
    • 非洲
  • 亚太地区

第十七章 基因治疗市场：依组别划分

  • ASEAN
  • GCC
  • EU
  • BRICS
  • G7
  • NATO

第十八章 基因治疗市场：依国家划分

  • 我们
  • 加拿大
  • 墨西哥
  • 巴西
  • 英国
  • 德国
  • 法国
  • 俄罗斯
  • 义大利
  • 西班牙
  • 中国
  • 印度
  • 日本
  • 澳洲
  • 韩国

第十九章：美国基因治疗市场

第二十章：中国的基因治疗市场

第21章 竞争情势

  • 市场集中度分析（2025 年）
    • 浓度比（CR）
    • 赫芬达尔-赫希曼指数 (HHI)
  • 近期趋势及影响分析（2025 年）
  • 产品系列分析（2025 年）
  • 基准分析（2025 年）
  • Abeona Therapeutics Inc.
  • Adaptimmune Therapeutics PLC
  • Adverum Biotechnologies, Inc.
  • AGC Biologics
  • Alnylam Pharmaceuticals, Inc.
  • American Gene Technologies Inc.
  • Amgen Inc.
  • AnGes, Inc.
  • Astellas Pharma Inc.
  • Biogen Inc.
  • bluebird bio, Inc.
  • Cellectis SA
  • CRISPR Therapeutics AG
  • Danaher Corporation
  • Editas Medicine, Inc.
  • F. Hoffmann-La Roche Ltd.
  • Gilead Sciences, Inc.
  • Intellia Therapeutics
  • Ionis Pharmaceuticals, Inc.
  • Johnson & Johnson
  • Merck KGaA
  • Mustang Bio, Inc.
  • Novartis AG
  • Orchard Therapeutics PLC
  • Poseida Therapeutics, Inc.
  • Sangamo Therapeutics, Inc.
  • Sarepta Therapeutics, Inc.
  • Sibiono GeneTech Co. Ltd.
  • Syncona Limited
  • ViGeneron GmbH
  • Voyager Therapeutics Inc.
Product Code: MRR-437517DB6C62

The Gene Therapy Market was valued at USD 12.91 billion in 2025 and is projected to grow to USD 16.35 billion in 2026, with a CAGR of 28.80%, reaching USD 75.92 billion by 2032.

KEY MARKET STATISTICS
Base Year [2025] USD 12.91 billion
Estimated Year [2026] USD 16.35 billion
Forecast Year [2032] USD 75.92 billion
CAGR (%) 28.80%

Contextualizing the evolution of gene therapy from experimental breakthroughs to integrated development and commercialization imperatives across stakeholders

The gene therapy field has moved from proof-of-concept demonstrations to a maturing ecosystem where clinical efficacy, regulatory clarity, and manufacturing scale converge to shape commercial pathways. Continued scientific breakthroughs in vector engineering and editing platforms, coupled with deeper understanding of long-term safety profiles, have expanded the set of treatable conditions and broadened investor and payer interest. As a result, strategic priorities now include not only accelerating clinical translation but also ensuring robust supply chains, standardized analytical methods, and sustainable manufacturing models that can support repeatable commercial launches.

Regulatory agencies globally are increasingly focused on harmonizing guidance around product characterization, potency assays, and long-term follow-up, which is influencing trial design and approval strategies. Concurrently, payers and health technology assessment bodies are testing innovative reimbursement mechanisms for one-time or durable therapies, prompting manufacturers to build more rigorous real-world evidence generation plans. This transition from single-asset breakthrough narratives to complex product life-cycle management demands integrated capabilities across R&D, regulatory strategy, manufacturing, and commercial operations.

In this context, decision makers must weigh technological choices-such as vector systems and delivery modes-against clinical objectives, patient populations, and logistical constraints. Interdisciplinary collaboration across academia, biotech, contract developers, and clinical networks is critical to shorten timelines while preserving safety and quality. The remainder of this executive summary synthesizes the structural shifts, policy impacts, segmentation-driven insights, regional dynamics, and practical recommendations to inform strategic investments and operational readiness across the gene therapy value chain.

Identifying concurrent technological, manufacturing, regulatory, and payer shifts that are redefining development priorities and commercial viability in gene therapy

The landscape for gene therapy is being reshaped by several transformative shifts that operate in parallel and reinforce one another. First, platform diversification has accelerated; vector technologies and genome modulation approaches have become more specialized, enabling therapies that are increasingly tailored to disease biology and patient subpopulations. This technical diversification has induced a reconfiguration of R&D pipelines, with early-stage programs emphasizing vector optimization, payload design, and manufacturability concurrently rather than sequentially.

Second, manufacturing and supply chain sophistication are emerging as strategic bottlenecks and differentiators. Developers are investing in modular, flexible manufacturing capacity and deeper engagements with contract development and manufacturing organizations to mitigate risks associated with vector scarcity and lot variability. This operational focus is complemented by a growing emphasis on analytical robustness and comparability studies to ensure batch consistency and regulatory acceptance.

Third, payer and health system conversations have moved from hypothetical affordability debates to concrete arrangements exploring outcomes-based contracts, annuity models, and real-world evidence commitments. These financing mechanisms are influencing pricing strategy, trial endpoint selection, and post-launch evidence programs. Lastly, regulatory maturation continues to be a major force, with agencies issuing iterative guidance and adopting expedited pathways for high-unmet-need indications, while also tightening expectations around long-term safety monitoring and product characterization. Together, these shifts demand integrated strategic planning that spans scientific, operational, and commercial disciplines.

Examining how United States tariff adjustments in 2025 amplified supply risk, reshaped sourcing strategies, and accelerated regional manufacturing investments across gene therapy

Tariff changes and trade policy shifts implemented in 2025 in the United States introduced new cost and logistical considerations for organizations operating in the gene therapy ecosystem. These policy adjustments have magnified the importance of geographically diversified supply chains and manufacturing footprints, as components, reagents, and specialized equipment traverse international borders with greater cost sensitivity. Companies are recalibrating sourcing strategies and inventory policies to absorb or pass through incremental import duties without compromising clinical timelines.

The immediate operational response has included prioritizing local content where feasible, accelerating qualification of alternative suppliers, and expanding regional manufacturing capacity to reduce cross-border exposure. For some developers, the added cost pressure has prompted renegotiation of vendor contracts and closer collaboration with contract manufacturers to identify mutual efficiencies. Over time, strategic capital allocation is shifting toward on-shore or near-shore capabilities for critical production steps, particularly vector manufacture and fill/finish operations, to insulate programs from tariff volatility.

At a program level, these trade dynamics also influence decision making around global trial design and site selection. Sponsors must balance the benefits of broader patient access and regulatory diversification against the added complexity and cost of cross-border logistics. In sum, tariff measures implemented in 2025 have reinforced a broader industry trend toward resilience through geographic diversification, supplier redundancy, and closer integration between commercial strategy and supply chain planning.

Articulating how vector selection, treatment modality, target genome, delivery mode, patient demographics, therapeutic focus, and end-user roles collectively shape strategic development choices

Segment-level dynamics reveal heterogeneous development pathways and operational requirements that materially affect clinical strategies and commercialization readiness. When analyzed by vector type, distinctions between non-viral and viral platforms are notable: non-viral approaches such as lipofection and plasmid DNA frequently offer advantages in dose control and manufacturing scalability, while viral platforms including adeno-associated virus vectors, adenovirus vectors, herpes simplex virus vectors, and retrovirus vectors continue to drive sustained clinical interest because of their transduction efficiency and tissue tropism. These intrinsic differences influence priorities in potency assay development, lot release criteria, and cold-chain logistics.

Treatment modality introduces regulatory and ethical complexity. Germline interventions remain subject to heightened ethical scrutiny and constrained pathways, whereas somatic cell therapies-comprising approaches that augment gene function and those that suppress deleterious expression-are the primary focus of near-term clinical translation. Choices between DNA modification and RNA modification as the target genome further affect therapeutic durability, off-target risk profiles, and analytical needs, with DNA editing approaches necessitating more extensive genomic characterization and RNA-targeting strategies demanding precise transient expression control.

Delivery mode is another pivotal segmentation axis, where ex vivo approaches require integrated cellular manipulation and manufacturing capabilities, while in vivo delivery places premium emphasis on vector biodistribution, immunogenicity mitigation, and systemic dosing strategies. Route of administration across intramuscular, intraocular, and intravenous pathways determines clinical trial design, safety monitoring, and procedural infrastructure at treatment centers. Patient type stratification between adult and pediatric populations drives differential endpoints, ethical considerations, and long-term follow-up commitments. Therapeutic area segmentation spanning cardiovascular, infectious, monogenic, and oncological disorders imposes diverse clinical evidence expectations; cardiovascular applications such as coronary artery disease and heart failure demand different endpoints and delivery paradigms than infectious disease targets like hepatitis B and HIV, while monogenic disorders including cystic fibrosis, hemophilia, and sickle cell anemia have unique durability and correctional benchmarks and oncology targets split between hematological malignancies and solid tumors require distinct manufacturing scales and combination strategies. End-user dynamics involve contract research organizations, hospitals and clinics, pharmaceutical and biotech companies, and research institutes, each bringing different capabilities and procurement models that affect adoption velocity and clinical readiness. Integrating these segmentation insights into program planning enables targeted investments and risk-adjusted timelines that align technological choice with clinical and commercial imperatives.

Explaining how regional regulatory, clinical, and manufacturing environments in the Americas, Europe Middle East & Africa, and Asia-Pacific inform strategic entry and operational decisions

Regional dynamics exert profound influence over regulatory approaches, clinical trial ecosystems, manufacturing investments, and partnership models. In the Americas, a robust innovation ecosystem and active capital markets have supported rapid clinical translation and multiple commercial launches, but this region also faces concentrated manufacturing demand that drives strategic investments in capacity expansion and supply chain resilience. Clinical networks and payer engagement in this region are increasingly central to evidence generation and reimbursement experimentation, shaping the commercialization playbook for novel therapies.

The Europe, Middle East & Africa region presents a mosaic of regulatory frameworks and health system structures, which requires nuanced market entry strategies. European centralized and national regulatory pathways encourage harmonized scientific discussion but necessitate tailored pricing and access approaches across jurisdictions. Middle Eastern and African markets show growing interest in capacity building, regional manufacturing partnerships, and clinical trial participation, offering alternative patient access routes but with variable infrastructure and reimbursement environments. Cross-region collaboration and technology transfer are becoming more common as sponsors seek to balance access goals with operational feasibility.

Asia-Pacific is characterized by a combination of large patient pools, emerging regulatory agility, and significant investments in biotechnology infrastructure across multiple countries. Several markets are proactively creating incentives to attract clinical trials and manufacturing projects, and local biopharma ecosystems are producing increasingly sophisticated partnerships. Differences in regulatory expectations and reimbursement readiness across the region require sponsors to adopt segmented entry plans and to invest in local evidence generation and stakeholder engagement to realize therapeutic impact.

Highlighting how strategic partnerships, manufacturing specialization, and capability investments are redefining competitive positioning and development pathways among leading companies

Company behaviors across the gene therapy ecosystem illustrate an emphasis on strategic partnering, vertical integration where feasible, and specialization that targets bottlenecks such as vector manufacture and analytical development. Biotech developers are increasingly forming long-term alliances with contract developers and manufacturing organizations to secure capacity and to co-invest in process improvements that reduce unit cost and enhance product consistency. Parallel to this, larger pharmaceutical companies are acquiring or licensing platform technologies to broaden therapeutic pipelines and to internalize specific capabilities around clinical development and commercial distribution.

Investment in in-house analytical capabilities and quality systems has become a competitive differentiator, enabling companies to accelerate comparability exercises and support accelerated regulatory pathways. There is also a notable trend toward modular manufacturing solutions and single-use technologies that can be deployed across multiple assets to improve flexibility. Strategic sourcing and supplier diversification are common, particularly for rare raw materials and specialized consumables. Companies are prioritizing talent development in highly technical areas such as vector biology, process development, and regulatory science, recognizing that human capital is critical to sustaining innovation and operational excellence.

From a corporate development perspective, licensing structures are evolving to include milestone and outcomes-linked economics, reflecting the increasing role of payers and the need to align incentives across stakeholders. These developments underscore the importance of adaptive commercial strategies that integrate development milestones, manufacturing readiness, and payer engagement plans early in program realization.

Prioritize integrated manufacturing, payer engagement, product design, regional operations, and cross-functional governance to convert gene therapy innovation into sustainable market success

Industry leaders should act decisively to translate scientific potential into durable commercial success by focusing on a handful of high-impact priorities. First, investment in scalable and flexible manufacturing capacity-whether through strategic partnerships or selective in-house build-will reduce program risk and enable more predictable launch timelines. Such investments should emphasize analytical rigor, process control, and supply chain diversity to guard against single-point failures and to facilitate regulatory interactions.

Second, early and ongoing payer engagement is essential to shape trial endpoints, real-world evidence plans, and reimbursement approaches that reflect both clinical value and system affordability. Designing evidence generation strategies that integrate clinical outcomes with health economic measures will improve access prospects and reduce post-launch friction. Third, prioritize technologies and program designs that balance biological potency with manufacturability; this includes choosing vectors, payload formats, and delivery routes that align with available production capabilities and clinical site readiness.

Fourth, adopt regionalized operational strategies that optimize the placement of manufacturing, clinical trials, and commercialization activities to minimize tariff exposure and logistics complexity while maximizing patient access. Finally, embed cross-functional governance structures that align R&D, regulatory, manufacturing, and commercial teams from program inception through launch to ensure coherent decision making and to accelerate value realization. By operationalizing these priorities, industry leaders can reduce time-to-patient and improve the overall sustainability of gene therapy portfolios.

Describing a transparent, triangulated research methodology that integrates expert interviews, scientific literature, regulatory guidance, and supply-chain analysis to generate actionable insights

The research approach underpinning this executive summary combined a structured synthesis of publicly available scientific literature, regulatory guidance, and industry disclosures with qualitative insights from interviews with subject matter experts across development, manufacturing, regulation, and commercial strategy. Primary inputs included conversations with developers, third-party manufacturers, clinical investigators, and payer advisors to surface practical constraints and strategic responses that are not always evident in formal publications. Secondary research emphasized peer-reviewed studies, regulatory agency communications, and technical white papers to corroborate mechanistic and technological assertions.

Data triangulation was applied to reconcile diverse perspectives and to validate thematic conclusions, with a focus on reproducibility and methodological transparency. Where trade policy impacts and regional dynamics were discussed, triangulation included public policy announcements and industry supply-chain commentaries. The methodology acknowledges limitations associated with rapidly evolving scientific data and the proprietary nature of many commercial arrangements; therefore, qualitative findings were blended with technical literature to build robust, contextualized insights rather than to produce quantitative projections.

Ethical standards for research integrity and confidentiality were maintained during expert consultations, and potential conflicts of interest were managed through disclosure and source diversification. The research design emphasizes actionable insight generation and strategic relevance for decision makers considering investment, partnership, or operational commitments in gene therapy development and commercialization.

Summarizing how scientific advances, operational readiness, and payer and regulatory expectations converge to determine which gene therapy programs achieve sustained clinical and commercial impact

Gene therapy is at an inflection point where scientific maturity and commercial complexity intersect. Advances in vector engineering, genome modulation technologies, and clinical experience have expanded the therapeutic horizon, but success increasingly depends on operational excellence across manufacturing, analytics, and supply chain management. Regulatory agencies and payers are refining expectations, driving developers to align clinical design and evidence plans with long-term safety and value demonstration imperatives. This confluence elevates the importance of integrated strategic planning that anticipates manufacturing constraints, regional regulatory variability, and payer negotiations.

Organizations that adopt a holistic approach-where technology selection, patient population strategy, site readiness, and reimbursement planning are developed in parallel-will be better positioned to translate scientific promise into sustained clinical and commercial outcomes. Building resilient and flexible operations, investing in critical analytical capabilities, and fostering collaborative partnerships across the ecosystem are practical levers to manage technical and policy uncertainties. As the field continues to evolve, success will favor those who balance scientific ambition with pragmatic, execution-oriented strategies that prioritize patient access and long-term safety monitoring.

This summary distills current structural drivers and operational imperatives intended to inform executive decision making and to guide prioritized investments necessary for advancing gene therapies from experimental success to durable clinical impact.

Table of Contents

1. Preface

  • 1.1. Objectives of the Study
  • 1.2. Market Definition
  • 1.3. Market Segmentation & Coverage
  • 1.4. Years Considered for the Study
  • 1.5. Currency Considered for the Study
  • 1.6. Language Considered for the Study
  • 1.7. Key Stakeholders

2. Research Methodology

  • 2.1. Introduction
  • 2.2. Research Design
    • 2.2.1. Primary Research
    • 2.2.2. Secondary Research
  • 2.3. Research Framework
    • 2.3.1. Qualitative Analysis
    • 2.3.2. Quantitative Analysis
  • 2.4. Market Size Estimation
    • 2.4.1. Top-Down Approach
    • 2.4.2. Bottom-Up Approach
  • 2.5. Data Triangulation
  • 2.6. Research Outcomes
  • 2.7. Research Assumptions
  • 2.8. Research Limitations

3. Executive Summary

  • 3.1. Introduction
  • 3.2. CXO Perspective
  • 3.3. Market Size & Growth Trends
  • 3.4. Market Share Analysis, 2025
  • 3.5. FPNV Positioning Matrix, 2025
  • 3.6. New Revenue Opportunities
  • 3.7. Next-Generation Business Models
  • 3.8. Industry Roadmap

4. Market Overview

  • 4.1. Introduction
  • 4.2. Industry Ecosystem & Value Chain Analysis
    • 4.2.1. Supply-Side Analysis
    • 4.2.2. Demand-Side Analysis
    • 4.2.3. Stakeholder Analysis
  • 4.3. Porter's Five Forces Analysis
  • 4.4. PESTLE Analysis
  • 4.5. Market Outlook
    • 4.5.1. Near-Term Market Outlook (0-2 Years)
    • 4.5.2. Medium-Term Market Outlook (3-5 Years)
    • 4.5.3. Long-Term Market Outlook (5-10 Years)
  • 4.6. Go-to-Market Strategy

5. Market Insights

  • 5.1. Consumer Insights & End-User Perspective
  • 5.2. Consumer Experience Benchmarking
  • 5.3. Opportunity Mapping
  • 5.4. Distribution Channel Analysis
  • 5.5. Pricing Trend Analysis
  • 5.6. Regulatory Compliance & Standards Framework
  • 5.7. ESG & Sustainability Analysis
  • 5.8. Disruption & Risk Scenarios
  • 5.9. Return on Investment & Cost-Benefit Analysis

6. Cumulative Impact of United States Tariffs 2025

7. Cumulative Impact of Artificial Intelligence 2025

8. Gene Therapy Market, by Vector Type

  • 8.1. Non-Viral Vectors
    • 8.1.1. Lipofection
    • 8.1.2. Plasmid DNA
  • 8.2. Viral Vectors
    • 8.2.1. Adeno-Associated Virus (AAV) Vectors
    • 8.2.2. Adenovirus Vectors
    • 8.2.3. Herpes Simplex Virus (HSV) Vectors
    • 8.2.4. Retrovirus Vectors

9. Gene Therapy Market, by Treatment Modality

  • 9.1. Germline Therapy
  • 9.2. Somatic Cell Therapy
    • 9.2.1. Gene Augmentation Therapy
    • 9.2.2. Gene Suppression Therapy

10. Gene Therapy Market, by Target Genome

  • 10.1. DNA Modification
  • 10.2. RNA Modification

11. Gene Therapy Market, by Delivery Mode

  • 11.1. Ex Vivo
  • 11.2. In Vivo

12. Gene Therapy Market, by Route of Administration

  • 12.1. Intramuscular
  • 12.2. Intraocular
  • 12.3. Intravenous

13. Gene Therapy Market, by Patient Type

  • 13.1. Adult Patients
  • 13.2. Pediatric Patients

14. Gene Therapy Market, by Therapeutic Area

  • 14.1. Cardiovascular Diseases
    • 14.1.1. Coronary Artery Disease
    • 14.1.2. Heart Failure
  • 14.2. Infectious Diseases
    • 14.2.1. Hepatitis B
    • 14.2.2. HIV
  • 14.3. Monogenic Disorders
    • 14.3.1. Cystic Fibrosis
    • 14.3.2. Hemophilia
    • 14.3.3. Sickle Cell Anemia
  • 14.4. Oncological Disorders
    • 14.4.1. Hematological Malignancies
    • 14.4.2. Solid Tumors

15. Gene Therapy Market, by End-User

  • 15.1. Contract Research Organizations
  • 15.2. Hospitals & Clinics
  • 15.3. Pharmaceutical & Biotech Companies
  • 15.4. Research Institutes

16. Gene Therapy Market, by Region

  • 16.1. Americas
    • 16.1.1. North America
    • 16.1.2. Latin America
  • 16.2. Europe, Middle East & Africa
    • 16.2.1. Europe
    • 16.2.2. Middle East
    • 16.2.3. Africa
  • 16.3. Asia-Pacific

17. Gene Therapy Market, by Group

  • 17.1. ASEAN
  • 17.2. GCC
  • 17.3. European Union
  • 17.4. BRICS
  • 17.5. G7
  • 17.6. NATO

18. Gene Therapy Market, by Country

  • 18.1. United States
  • 18.2. Canada
  • 18.3. Mexico
  • 18.4. Brazil
  • 18.5. United Kingdom
  • 18.6. Germany
  • 18.7. France
  • 18.8. Russia
  • 18.9. Italy
  • 18.10. Spain
  • 18.11. China
  • 18.12. India
  • 18.13. Japan
  • 18.14. Australia
  • 18.15. South Korea

19. United States Gene Therapy Market

20. China Gene Therapy Market

21. Competitive Landscape

  • 21.1. Market Concentration Analysis, 2025
    • 21.1.1. Concentration Ratio (CR)
    • 21.1.2. Herfindahl Hirschman Index (HHI)
  • 21.2. Recent Developments & Impact Analysis, 2025
  • 21.3. Product Portfolio Analysis, 2025
  • 21.4. Benchmarking Analysis, 2025
  • 21.5. Abeona Therapeutics Inc.
  • 21.6. Adaptimmune Therapeutics PLC
  • 21.7. Adverum Biotechnologies, Inc.
  • 21.8. AGC Biologics
  • 21.9. Alnylam Pharmaceuticals, Inc.
  • 21.10. American Gene Technologies Inc.
  • 21.11. Amgen Inc.
  • 21.12. AnGes, Inc.
  • 21.13. Astellas Pharma Inc.
  • 21.14. Biogen Inc.
  • 21.15. bluebird bio, Inc.
  • 21.16. Cellectis S.A.
  • 21.17. CRISPR Therapeutics AG
  • 21.18. Danaher Corporation
  • 21.19. Editas Medicine, Inc.
  • 21.20. F. Hoffmann-La Roche Ltd.
  • 21.21. Gilead Sciences, Inc.
  • 21.22. Intellia Therapeutics
  • 21.23. Ionis Pharmaceuticals, Inc.
  • 21.24. Johnson & Johnson
  • 21.25. Merck KGaA
  • 21.26. Mustang Bio, Inc.
  • 21.27. Novartis AG
  • 21.28. Orchard Therapeutics PLC
  • 21.29. Poseida Therapeutics, Inc.
  • 21.30. Sangamo Therapeutics, Inc.
  • 21.31. Sarepta Therapeutics, Inc.
  • 21.32. Sibiono GeneTech Co. Ltd.
  • 21.33. Syncona Limited
  • 21.34. ViGeneron GmbH
  • 21.35. Voyager Therapeutics Inc.

LIST OF FIGURES

  • FIGURE 1. GLOBAL GENE THERAPY MARKET SIZE, 2018-2032 (USD MILLION)
  • FIGURE 2. GLOBAL GENE THERAPY MARKET SHARE, BY KEY PLAYER, 2025
  • FIGURE 3. GLOBAL GENE THERAPY MARKET, FPNV POSITIONING MATRIX, 2025
  • FIGURE 4. GLOBAL GENE THERAPY MARKET SIZE, BY VECTOR TYPE, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 5. GLOBAL GENE THERAPY MARKET SIZE, BY TREATMENT MODALITY, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 6. GLOBAL GENE THERAPY MARKET SIZE, BY TARGET GENOME, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 7. GLOBAL GENE THERAPY MARKET SIZE, BY DELIVERY MODE, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 8. GLOBAL GENE THERAPY MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 9. GLOBAL GENE THERAPY MARKET SIZE, BY PATIENT TYPE, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 10. GLOBAL GENE THERAPY MARKET SIZE, BY THERAPEUTIC AREA, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 11. GLOBAL GENE THERAPY MARKET SIZE, BY END-USER, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 12. GLOBAL GENE THERAPY MARKET SIZE, BY REGION, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 13. GLOBAL GENE THERAPY MARKET SIZE, BY GROUP, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 14. GLOBAL GENE THERAPY MARKET SIZE, BY COUNTRY, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 15. UNITED STATES GENE THERAPY MARKET SIZE, 2018-2032 (USD MILLION)
  • FIGURE 16. CHINA GENE THERAPY MARKET SIZE, 2018-2032 (USD MILLION)

LIST OF TABLES

  • TABLE 1. GLOBAL GENE THERAPY MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 2. GLOBAL GENE THERAPY MARKET SIZE, BY VECTOR TYPE, 2018-2032 (USD MILLION)
  • TABLE 3. GLOBAL GENE THERAPY MARKET SIZE, BY NON-VIRAL VECTORS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 4. GLOBAL GENE THERAPY MARKET SIZE, BY NON-VIRAL VECTORS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 5. GLOBAL GENE THERAPY MARKET SIZE, BY NON-VIRAL VECTORS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 6. GLOBAL GENE THERAPY MARKET SIZE, BY NON-VIRAL VECTORS, 2018-2032 (USD MILLION)
  • TABLE 7. GLOBAL GENE THERAPY MARKET SIZE, BY LIPOFECTION, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 8. GLOBAL GENE THERAPY MARKET SIZE, BY LIPOFECTION, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 9. GLOBAL GENE THERAPY MARKET SIZE, BY LIPOFECTION, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 10. GLOBAL GENE THERAPY MARKET SIZE, BY PLASMID DNA, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 11. GLOBAL GENE THERAPY MARKET SIZE, BY PLASMID DNA, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 12. GLOBAL GENE THERAPY MARKET SIZE, BY PLASMID DNA, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 13. GLOBAL GENE THERAPY MARKET SIZE, BY VIRAL VECTORS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 14. GLOBAL GENE THERAPY MARKET SIZE, BY VIRAL VECTORS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 15. GLOBAL GENE THERAPY MARKET SIZE, BY VIRAL VECTORS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 16. GLOBAL GENE THERAPY MARKET SIZE, BY VIRAL VECTORS, 2018-2032 (USD MILLION)
  • TABLE 17. GLOBAL GENE THERAPY MARKET SIZE, BY ADENO-ASSOCIATED VIRUS (AAV) VECTORS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 18. GLOBAL GENE THERAPY MARKET SIZE, BY ADENO-ASSOCIATED VIRUS (AAV) VECTORS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 19. GLOBAL GENE THERAPY MARKET SIZE, BY ADENO-ASSOCIATED VIRUS (AAV) VECTORS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 20. GLOBAL GENE THERAPY MARKET SIZE, BY ADENOVIRUS VECTORS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 21. GLOBAL GENE THERAPY MARKET SIZE, BY ADENOVIRUS VECTORS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 22. GLOBAL GENE THERAPY MARKET SIZE, BY ADENOVIRUS VECTORS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 23. GLOBAL GENE THERAPY MARKET SIZE, BY HERPES SIMPLEX VIRUS (HSV) VECTORS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 24. GLOBAL GENE THERAPY MARKET SIZE, BY HERPES SIMPLEX VIRUS (HSV) VECTORS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 25. GLOBAL GENE THERAPY MARKET SIZE, BY HERPES SIMPLEX VIRUS (HSV) VECTORS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 26. GLOBAL GENE THERAPY MARKET SIZE, BY RETROVIRUS VECTORS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 27. GLOBAL GENE THERAPY MARKET SIZE, BY RETROVIRUS VECTORS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 28. GLOBAL GENE THERAPY MARKET SIZE, BY RETROVIRUS VECTORS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 29. GLOBAL GENE THERAPY MARKET SIZE, BY TREATMENT MODALITY, 2018-2032 (USD MILLION)
  • TABLE 30. GLOBAL GENE THERAPY MARKET SIZE, BY GERMLINE THERAPY, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 31. GLOBAL GENE THERAPY MARKET SIZE, BY GERMLINE THERAPY, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 32. GLOBAL GENE THERAPY MARKET SIZE, BY GERMLINE THERAPY, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 33. GLOBAL GENE THERAPY MARKET SIZE, BY SOMATIC CELL THERAPY, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 34. GLOBAL GENE THERAPY MARKET SIZE, BY SOMATIC CELL THERAPY, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 35. GLOBAL GENE THERAPY MARKET SIZE, BY SOMATIC CELL THERAPY, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 36. GLOBAL GENE THERAPY MARKET SIZE, BY SOMATIC CELL THERAPY, 2018-2032 (USD MILLION)
  • TABLE 37. GLOBAL GENE THERAPY MARKET SIZE, BY GENE AUGMENTATION THERAPY, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 38. GLOBAL GENE THERAPY MARKET SIZE, BY GENE AUGMENTATION THERAPY, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 39. GLOBAL GENE THERAPY MARKET SIZE, BY GENE AUGMENTATION THERAPY, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 40. GLOBAL GENE THERAPY MARKET SIZE, BY GENE SUPPRESSION THERAPY, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 41. GLOBAL GENE THERAPY MARKET SIZE, BY GENE SUPPRESSION THERAPY, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 42. GLOBAL GENE THERAPY MARKET SIZE, BY GENE SUPPRESSION THERAPY, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 43. GLOBAL GENE THERAPY MARKET SIZE, BY TARGET GENOME, 2018-2032 (USD MILLION)
  • TABLE 44. GLOBAL GENE THERAPY MARKET SIZE, BY DNA MODIFICATION, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 45. GLOBAL GENE THERAPY MARKET SIZE, BY DNA MODIFICATION, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 46. GLOBAL GENE THERAPY MARKET SIZE, BY DNA MODIFICATION, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 47. GLOBAL GENE THERAPY MARKET SIZE, BY RNA MODIFICATION, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 48. GLOBAL GENE THERAPY MARKET SIZE, BY RNA MODIFICATION, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 49. GLOBAL GENE THERAPY MARKET SIZE, BY RNA MODIFICATION, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 50. GLOBAL GENE THERAPY MARKET SIZE, BY DELIVERY MODE, 2018-2032 (USD MILLION)
  • TABLE 51. GLOBAL GENE THERAPY MARKET SIZE, BY EX VIVO, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 52. GLOBAL GENE THERAPY MARKET SIZE, BY EX VIVO, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 53. GLOBAL GENE THERAPY MARKET SIZE, BY EX VIVO, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 54. GLOBAL GENE THERAPY MARKET SIZE, BY IN VIVO, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 55. GLOBAL GENE THERAPY MARKET SIZE, BY IN VIVO, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 56. GLOBAL GENE THERAPY MARKET SIZE, BY IN VIVO, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 57. GLOBAL GENE THERAPY MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 58. GLOBAL GENE THERAPY MARKET SIZE, BY INTRAMUSCULAR, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 59. GLOBAL GENE THERAPY MARKET SIZE, BY INTRAMUSCULAR, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 60. GLOBAL GENE THERAPY MARKET SIZE, BY INTRAMUSCULAR, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 61. GLOBAL GENE THERAPY MARKET SIZE, BY INTRAOCULAR, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 62. GLOBAL GENE THERAPY MARKET SIZE, BY INTRAOCULAR, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 63. GLOBAL GENE THERAPY MARKET SIZE, BY INTRAOCULAR, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 64. GLOBAL GENE THERAPY MARKET SIZE, BY INTRAVENOUS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 65. GLOBAL GENE THERAPY MARKET SIZE, BY INTRAVENOUS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 66. GLOBAL GENE THERAPY MARKET SIZE, BY INTRAVENOUS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 67. GLOBAL GENE THERAPY MARKET SIZE, BY PATIENT TYPE, 2018-2032 (USD MILLION)
  • TABLE 68. GLOBAL GENE THERAPY MARKET SIZE, BY ADULT PATIENTS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 69. GLOBAL GENE THERAPY MARKET SIZE, BY ADULT PATIENTS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 70. GLOBAL GENE THERAPY MARKET SIZE, BY ADULT PATIENTS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 71. GLOBAL GENE THERAPY MARKET SIZE, BY PEDIATRIC PATIENTS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 72. GLOBAL GENE THERAPY MARKET SIZE, BY PEDIATRIC PATIENTS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 73. GLOBAL GENE THERAPY MARKET SIZE, BY PEDIATRIC PATIENTS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 74. GLOBAL GENE THERAPY MARKET SIZE, BY THERAPEUTIC AREA, 2018-2032 (USD MILLION)
  • TABLE 75. GLOBAL GENE THERAPY MARKET SIZE, BY CARDIOVASCULAR DISEASES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 76. GLOBAL GENE THERAPY MARKET SIZE, BY CARDIOVASCULAR DISEASES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 77. GLOBAL GENE THERAPY MARKET SIZE, BY CARDIOVASCULAR DISEASES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 78. GLOBAL GENE THERAPY MARKET SIZE, BY CARDIOVASCULAR DISEASES, 2018-2032 (USD MILLION)
  • TABLE 79. GLOBAL GENE THERAPY MARKET SIZE, BY CORONARY ARTERY DISEASE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 80. GLOBAL GENE THERAPY MARKET SIZE, BY CORONARY ARTERY DISEASE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 81. GLOBAL GENE THERAPY MARKET SIZE, BY CORONARY ARTERY DISEASE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 82. GLOBAL GENE THERAPY MARKET SIZE, BY HEART FAILURE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 83. GLOBAL GENE THERAPY MARKET SIZE, BY HEART FAILURE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 84. GLOBAL GENE THERAPY MARKET SIZE, BY HEART FAILURE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 85. GLOBAL GENE THERAPY MARKET SIZE, BY INFECTIOUS DISEASES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 86. GLOBAL GENE THERAPY MARKET SIZE, BY INFECTIOUS DISEASES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 87. GLOBAL GENE THERAPY MARKET SIZE, BY INFECTIOUS DISEASES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 88. GLOBAL GENE THERAPY MARKET SIZE, BY INFECTIOUS DISEASES, 2018-2032 (USD MILLION)
  • TABLE 89. GLOBAL GENE THERAPY MARKET SIZE, BY HEPATITIS B, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 90. GLOBAL GENE THERAPY MARKET SIZE, BY HEPATITIS B, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 91. GLOBAL GENE THERAPY MARKET SIZE, BY HEPATITIS B, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 92. GLOBAL GENE THERAPY MARKET SIZE, BY HIV, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 93. GLOBAL GENE THERAPY MARKET SIZE, BY HIV, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 94. GLOBAL GENE THERAPY MARKET SIZE, BY HIV, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 95. GLOBAL GENE THERAPY MARKET SIZE, BY MONOGENIC DISORDERS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 96. GLOBAL GENE THERAPY MARKET SIZE, BY MONOGENIC DISORDERS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 97. GLOBAL GENE THERAPY MARKET SIZE, BY MONOGENIC DISORDERS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 98. GLOBAL GENE THERAPY MARKET SIZE, BY MONOGENIC DISORDERS, 2018-2032 (USD MILLION)
  • TABLE 99. GLOBAL GENE THERAPY MARKET SIZE, BY CYSTIC FIBROSIS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 100. GLOBAL GENE THERAPY MARKET SIZE, BY CYSTIC FIBROSIS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 101. GLOBAL GENE THERAPY MARKET SIZE, BY CYSTIC FIBROSIS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 102. GLOBAL GENE THERAPY MARKET SIZE, BY HEMOPHILIA, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 103. GLOBAL GENE THERAPY MARKET SIZE, BY HEMOPHILIA, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 104. GLOBAL GENE THERAPY MARKET SIZE, BY HEMOPHILIA, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 105. GLOBAL GENE THERAPY MARKET SIZE, BY SICKLE CELL ANEMIA, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 106. GLOBAL GENE THERAPY MARKET SIZE, BY SICKLE CELL ANEMIA, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 107. GLOBAL GENE THERAPY MARKET SIZE, BY SICKLE CELL ANEMIA, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 108. GLOBAL GENE THERAPY MARKET SIZE, BY ONCOLOGICAL DISORDERS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 109. GLOBAL GENE THERAPY MARKET SIZE, BY ONCOLOGICAL DISORDERS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 110. GLOBAL GENE THERAPY MARKET SIZE, BY ONCOLOGICAL DISORDERS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 111. GLOBAL GENE THERAPY MARKET SIZE, BY ONCOLOGICAL DISORDERS, 2018-2032 (USD MILLION)
  • TABLE 112. GLOBAL GENE THERAPY MARKET SIZE, BY HEMATOLOGICAL MALIGNANCIES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 113. GLOBAL GENE THERAPY MARKET SIZE, BY HEMATOLOGICAL MALIGNANCIES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 114. GLOBAL GENE THERAPY MARKET SIZE, BY HEMATOLOGICAL MALIGNANCIES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 115. GLOBAL GENE THERAPY MARKET SIZE, BY SOLID TUMORS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 116. GLOBAL GENE THERAPY MARKET SIZE, BY SOLID TUMORS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 117. GLOBAL GENE THERAPY MARKET SIZE, BY SOLID TUMORS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 118. GLOBAL GENE THERAPY MARKET SIZE, BY END-USER, 2018-2032 (USD MILLION)
  • TABLE 119. GLOBAL GENE THERAPY MARKET SIZE, BY CONTRACT RESEARCH ORGANIZATIONS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 120. GLOBAL GENE THERAPY MARKET SIZE, BY CONTRACT RESEARCH ORGANIZATIONS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 121. GLOBAL GENE THERAPY MARKET SIZE, BY CONTRACT RESEARCH ORGANIZATIONS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 122. GLOBAL GENE THERAPY MARKET SIZE, BY HOSPITALS & CLINICS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 123. GLOBAL GENE THERAPY MARKET SIZE, BY HOSPITALS & CLINICS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 124. GLOBAL GENE THERAPY MARKET SIZE, BY HOSPITALS & CLINICS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 125. GLOBAL GENE THERAPY MARKET SIZE, BY PHARMACEUTICAL & BIOTECH COMPANIES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 126. GLOBAL GENE THERAPY MARKET SIZE, BY PHARMACEUTICAL & BIOTECH COMPANIES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 127. GLOBAL GENE THERAPY MARKET SIZE, BY PHARMACEUTICAL & BIOTECH COMPANIES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 128. GLOBAL GENE THERAPY MARKET SIZE, BY RESEARCH INSTITUTES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 129. GLOBAL GENE THERAPY MARKET SIZE, BY RESEARCH INSTITUTES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 130. GLOBAL GENE THERAPY MARKET SIZE, BY RESEARCH INSTITUTES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 131. GLOBAL GENE THERAPY MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 132. AMERICAS GENE THERAPY MARKET SIZE, BY SUBREGION, 2018-2032 (USD MILLION)
  • TABLE 133. AMERICAS GENE THERAPY MARKET SIZE, BY VECTOR TYPE, 2018-2032 (USD MILLION)
  • TABLE 134. AMERICAS GENE THERAPY MARKET SIZE, BY NON-VIRAL VECTORS, 2018-2032 (USD MILLION)
  • TABLE 135. AMERICAS GENE THERAPY MARKET SIZE, BY VIRAL VECTORS, 2018-2032 (USD MILLION)
  • TABLE 136. AMERICAS GENE THERAPY MARKET SIZE, BY TREATMENT MODALITY, 2018-2032 (USD MILLION)
  • TABLE 137. AMERICAS GENE THERAPY MARKET SIZE, BY SOMATIC CELL THERAPY, 2018-2032 (USD MILLION)
  • TABLE 138. AMERICAS GENE THERAPY MARKET SIZE, BY TARGET GENOME, 2018-2032 (USD MILLION)
  • TABLE 139. AMERICAS GENE THERAPY MARKET SIZE, BY DELIVERY MODE, 2018-2032 (USD MILLION)
  • TABLE 140. AMERICAS GENE THERAPY MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 141. AMERICAS GENE THERAPY MARKET SIZE, BY PATIENT TYPE, 2018-2032 (USD MILLION)
  • TABLE 142. AMERICAS GENE THERAPY MARKET SIZE, BY THERAPEUTIC AREA, 2018-2032 (USD MILLION)
  • TABLE 143. AMERICAS GENE THERAPY MARKET SIZE, BY CARDIOVASCULAR DISEASES, 2018-2032 (USD MILLION)
  • TABLE 144. AMERICAS GENE THERAPY MARKET SIZE, BY INFECTIOUS DISEASES, 2018-2032 (USD MILLION)
  • TABLE 145. AMERICAS GENE THERAPY MARKET SIZE, BY MONOGENIC DISORDERS, 2018-2032 (USD MILLION)
  • TABLE 146. AMERICAS GENE THERAPY MARKET SIZE, BY ONCOLOGICAL DISORDERS, 2018-2032 (USD MILLION)
  • TABLE 147. AMERICAS GENE THERAPY MARKET SIZE, BY END-USER, 2018-2032 (USD MILLION)
  • TABLE 148. NORTH AMERICA GENE THERAPY MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 149. NORTH AMERICA GENE THERAPY MARKET SIZE, BY VECTOR TYPE, 2018-2032 (USD MILLION)
  • TABLE 150. NORTH AMERICA GENE THERAPY MARKET SIZE, BY NON-VIRAL VECTORS, 2018-2032 (USD MILLION)
  • TABLE 151. NORTH AMERICA GENE THERAPY MARKET SIZE, BY VIRAL VECTORS, 2018-2032 (USD MILLION)
  • TABLE 152. NORTH AMERICA GENE THERAPY MARKET SIZE, BY TREATMENT MODALITY, 2018-2032 (USD MILLION)
  • TABLE 153. NORTH AMERICA GENE THERAPY MARKET SIZE, BY SOMATIC CELL THERAPY, 2018-2032 (USD MILLION)
  • TABLE 154. NORTH AMERICA GENE THERAPY MARKET SIZE, BY TARGET GENOME, 2018-2032 (USD MILLION)
  • TABLE 155. NORTH AMERICA GENE THERAPY MARKET SIZE, BY DELIVERY MODE, 2018-2032 (USD MILLION)
  • TABLE 156. NORTH AMERICA GENE THERAPY MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 157. NORTH AMERICA GENE THERAPY MARKET SIZE, BY PATIENT TYPE, 2018-2032 (USD MILLION)
  • TABLE 158. NORTH AMERICA GENE THERAPY MARKET SIZE, BY THERAPEUTIC AREA, 2018-2032 (USD MILLION)
  • TABLE 159. NORTH AMERICA GENE THERAPY MARKET SIZE, BY CARDIOVASCULAR DISEASES, 2018-2032 (USD MILLION)
  • TABLE 160. NORTH AMERICA GENE THERAPY MARKET SIZE, BY INFECTIOUS DISEASES, 2018-2032 (USD MILLION)
  • TABLE 161. NORTH AMERICA GENE THERAPY MARKET SIZE, BY MONOGENIC DISORDERS, 2018-2032 (USD MILLION)
  • TABLE 162. NORTH AMERICA GENE THERAPY MARKET SIZE, BY ONCOLOGICAL DISORDERS, 2018-2032 (USD MILLION)
  • TABLE 163. NORTH AMERICA GENE THERAPY MARKET SIZE, BY END-USER, 2018-2032 (USD MILLION)
  • TABLE 164. LATIN AMERICA GENE THERAPY MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 165. LATIN AMERICA GENE THERAPY MARKET SIZE, BY VECTOR TYPE, 2018-2032 (USD MILLION)
  • TABLE 166. LATIN AMERICA GENE THERAPY MARKET SIZE, BY NON-VIRAL VECTORS, 2018-2032 (USD MILLION)
  • TABLE 167. LATIN AMERICA GENE THERAPY MARKET SIZE, BY VIRAL VECTORS, 2018-2032 (USD MILLION)
  • TABLE 168. LATIN AMERICA GENE THERAPY MARKET SIZE, BY TREATMENT MODALITY, 2018-2032 (USD MILLION)
  • TABLE 169. LATIN AMERICA GENE THERAPY MARKET SIZE, BY SOMATIC CELL THERAPY, 2018-2032 (USD MILLION)
  • TABLE 170. LATIN AMERICA GENE THERAPY MARKET SIZE, BY TARGET GENOME, 2018-2032 (USD MILLION)
  • TABLE 171. LATIN AMERICA GENE THERAPY MARKET SIZE, BY DELIVERY MODE, 2018-2032 (USD MILLION)
  • TABLE 172. LATIN AMERICA GENE THERAPY MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 173. LATIN AMERICA GENE THERAPY MARKET SIZE, BY PATIENT TYPE, 2018-2032 (USD MILLION)
  • TABLE 174. LATIN AMERICA GENE THERAPY MARKET SIZE, BY THERAPEUTIC AREA, 2018-2032 (USD MILLION)
  • TABLE 175. LATIN AMERICA GENE THERAPY MARKET SIZE, BY CARDIOVASCULAR DISEASES, 2018-2032 (USD MILLION)
  • TABLE 176. LATIN AMERICA GENE THERAPY MARKET SIZE, BY INFECTIOUS DISEASES, 2018-2032 (USD MILLION)
  • TABLE 177. LATIN AMERICA GENE THERAPY MARKET SIZE, BY MONOGENIC DISORDERS, 2018-2032 (USD MILLION)
  • TABLE 178. LATIN AMERICA GENE THERAPY MARKET SIZE, BY ONCOLOGICAL DISORDERS, 2018-2032 (USD MILLION)
  • TABLE 179. LATIN AMERICA GENE THERAPY MARKET SIZE, BY END-USER, 2018-2032 (USD MILLION)
  • TABLE 180. EUROPE, MIDDLE EAST & AFRICA GENE THERAPY MARKET SIZE, BY SUBREGION, 2018-2032 (USD MILLION)
  • TABLE 181. EUROPE, MIDDLE EAST & AFRICA GENE THERAPY MARKET SIZE, BY VECTOR TYPE, 2018-2032 (USD MILLION)
  • TABLE 182. EUROPE, MIDDLE EAST & AFRICA GENE THERAPY MARKET SIZE, BY NON-VIRAL VECTORS, 2018-2032 (USD MILLION)
  • TABLE 183. EUROPE, MIDDLE EAST & AFRICA GENE THERAPY MARKET SIZE, BY VIRAL VECTORS, 2018-2032 (USD MILLION)
  • TABLE 184. EUROPE, MIDDLE EAST & AFRICA GENE THERAPY MARKET SIZE, BY TREATMENT MODALITY, 2018-2032 (USD MILLION)
  • TABLE 185. EUROPE, MIDDLE EAST & AFRICA GENE THERAPY MARKET SIZE, BY SOMATIC CELL THERAPY, 2018-2032 (USD MILLION)
  • TABLE 186. EUROPE, MIDDLE EAST & AFRICA GENE THERAPY MARKET SIZE, BY TARGET GENOME, 2018-2032 (USD MILLION)
  • TABLE 187. EUROPE, MIDDLE EAST & AFRICA GENE THERAPY MARKET SIZE, BY DELIVERY MODE, 2018-2032 (USD MILLION)
  • TABLE 188. EUROPE, MIDDLE EAST & AFRICA GENE THERAPY MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 189. EUROPE, MIDDLE EAST & AFRICA GENE THERAPY MARKET SIZE, BY PATIENT TYPE, 2018-2032 (USD MILLION)
  • TABLE 190. EUROPE, MIDDLE EAST & AFRICA GENE THERAPY MARKET SIZE, BY THERAPEUTIC AREA, 2018-2032 (USD MILLION)
  • TABLE 191. EUROPE, MIDDLE EAST & AFRICA GENE THERAPY MARKET SIZE, BY CARDIOVASCULAR DISEASES, 2018-2032 (USD MILLION)
  • TABLE 192. EUROPE, MIDDLE EAST & AFRICA GENE THERAPY MARKET SIZE, BY INFECTIOUS DISEASES, 2018-2032 (USD MILLION)
  • TABLE 193. EUROPE, MIDDLE EAST & AFRICA GENE THERAPY MARKET SIZE, BY MONOGENIC DISORDERS, 2018-2032 (USD MILLION)
  • TABLE 194. EUROPE, MIDDLE EAST & AFRICA GENE THERAPY MARKET SIZE, BY ONCOLOGICAL DISORDERS, 2018-2032 (USD MILLION)
  • TABLE 195. EUROPE, MIDDLE EAST & AFRICA GENE THERAPY MARKET SIZE, BY END-USER, 2018-2032 (USD MILLION)
  • TABLE 196. EUROPE GENE THERAPY MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 197. EUROPE GENE THERAPY MARKET SIZE, BY VECTOR TYPE, 2018-2032 (USD MILLION)
  • TABLE 198. EUROPE GENE THERAPY MARKET SIZE, BY NON-VIRAL VECTORS, 2018-2032 (USD MILLION)
  • TABLE 199. EUROPE GENE THERAPY MARKET SIZE, BY VIRAL VECTORS, 2018-2032 (USD MILLION)
  • TABLE 200. EUROPE GENE THERAPY MARKET SIZE, BY TREATMENT MODALITY, 2018-2032 (USD MILLION)
  • TABLE 201. EUROPE GENE THERAPY MARKET SIZE, BY SOMATIC CELL THERAPY, 2018-2032 (USD MILLION)
  • TABLE 202. EUROPE GENE THERAPY MARKET SIZE, BY TARGET GENOME, 2018-2032 (USD MILLION)
  • TABLE 203. EUROPE GENE THERAPY MARKET SIZE, BY DELIVERY MODE, 2018-2032 (USD MILLION)
  • TABLE 204. EUROPE GENE THERAPY MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 205. EUROPE GENE THERAPY MARKET SIZE, BY PATIENT TYPE, 2018-2032 (USD MILLION)
  • TABLE 206. EUROPE GENE THERAPY MARKET SIZE, BY THERAPEUTIC AREA, 2018-2032 (USD MILLION)
  • TABLE 207. EUROPE GENE THERAPY MARKET SIZE, BY CARDIOVASCULAR DISEASES, 2018-2032 (USD MILLION)
  • TABLE 208. EUROPE GENE THERAPY MARKET SIZE, BY INFECTIOUS DISEASES, 2018-2032 (USD MILLION)
  • TABLE 209. EUROPE GENE THERAPY MARKET SIZE, BY MONOGENIC DISORDERS, 2018-2032 (USD MILLION)
  • TABLE 210. EUROPE GENE THERAPY MARKET SIZE, BY ONCOLOGICAL DISORDERS, 2018-2032 (USD MILLION)
  • TABLE 211. EUROPE GENE THERAPY MARKET SIZE, BY END-USER, 2018-2032 (USD MILLION)
  • TABLE 212. MIDDLE EAST GENE THERAPY MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 213. MIDDLE EAST GENE THERAPY MARKET SIZE, BY VECTOR TYPE, 2018-2032 (USD MILLION)
  • TABLE 214. MIDDLE EAST GENE THERAPY MARKET SIZE, BY NON-VIRAL VECTORS, 2018-2032 (USD MILLION)
  • TABLE 215. MIDDLE EAST GENE THERAPY MARKET SIZE, BY VIRAL VECTORS, 2018-2032 (USD MILLION)
  • TABLE 216. MIDDLE EAST GENE THERAPY MARKET SIZE, BY TREATMENT MODALITY, 2018-2032 (USD MILLION)
  • TABLE 217. MIDDLE EAST GENE THERAPY MARKET SIZE, BY SOMATIC CELL THERAPY, 2018-2032 (USD MILLION)
  • TABLE 218. MIDDLE EAST GENE THERAPY MARKET SIZE, BY TARGET GENOME, 2018-2032 (USD MILLION)
  • TABLE 219. MIDDLE EAST GENE THERAPY MARKET SIZE, BY DELIVERY MODE, 2018-2032 (USD MILLION)
  • TABLE 220. MIDDLE EAST GENE THERAPY MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 221. MIDDLE EAST GENE THERAPY MARKET SIZE, BY PATIENT TYPE, 2018-2032 (USD MILLION)
  • TABLE 222. MIDDLE EAST GENE THERAPY MARKET SIZE, BY THERAPEUTIC AREA, 2018-2032 (USD MILLION)
  • TABLE 223. MIDDLE EAST GENE THERAPY MARKET SIZE, BY CARDIOVASCULAR DISEASES, 2018-2032 (USD MILLION)
  • TABLE 224. MIDDLE EAST GENE THERAPY MARKET SIZE, BY INFECTIOUS DISEASES, 2018-2032 (USD MILLION)
  • TABLE 225. MIDDLE EAST GENE THERAPY MARKET SIZE, BY MONOGENIC DISORDERS, 2018-2032 (USD MILLION)
  • TABLE 226. MIDDLE EAST GENE THERAPY MARKET SIZE, BY ONCOLOGICAL DISORDERS, 2018-2032 (USD MILLION)
  • TABLE 227. MIDDLE EAST GENE THERAPY MARKET SIZE, BY END-USER, 2018-2032 (USD MILLION)
  • TABLE 228. AFRICA GENE THERAPY MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 229. AFRICA GENE THERAPY MARKET SIZE, BY VECTOR TYPE, 2018-2032 (USD MILLION)
  • TABLE 230. AFRICA GENE THERAPY MARKET SIZE, BY NON-VIRAL VECTORS, 2018-2032 (USD MILLION)
  • TABLE 231. AFRICA GENE THERAPY MARKET SIZE, BY VIRAL VECTORS, 2018-2032 (USD MILLION)
  • TABLE 232. AFRICA GENE THERAPY MARKET SIZE, BY TREATMENT MODALITY, 2018-2032 (USD MILLION)
  • TABLE 233. AFRICA GENE THERAPY MARKET SIZE, BY SOMATIC CELL THERAPY, 2018-2032 (USD MILLION)
  • TABLE 234. AFRICA GENE THERAPY MARKET SIZE, BY TARGET GENOME, 2018-2032 (USD MILLION)
  • TABLE 235. AFRICA GENE THERAPY MARKET SIZE, BY DELIVERY MODE, 2018-2032 (USD MILLION)
  • TABLE 236. AFRICA GENE THERAPY MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 237. AFRICA GENE THERAPY MARKET SIZE, BY PATIENT TYPE, 2018-2032 (USD MILLION)
  • TABLE 238. AFRICA GENE THERAPY MARKET SIZE, BY THERAPEUTIC AREA, 2018-2032 (USD MILLION)
  • TABLE 239. AFRICA GENE THERAPY MARKET SIZE, BY CARDIOVASCULAR DISEASES, 2018-2032 (USD MILLION)
  • TABLE 240. AFRICA GENE THERAPY MARKET SIZE, BY INFECTIOUS DISEASES, 2018-2032 (USD MILLION)
  • TABLE 241. AFRICA GENE THERAPY MARKET SIZE, BY MONOGENIC DISORDERS, 2018-2032 (USD MILLION)
  • TABLE 242. AFRICA GENE THERAPY MARKET SIZE, BY ONCOLOGICAL DISORDERS, 2018-2032 (USD MILLION)
  • TABLE 243. AFRICA GENE THERAPY MARKET SIZE, BY END-USER, 2018-2032 (USD MILLION)
  • TABLE 244. ASIA-PACIFIC GENE THERAPY MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 245. ASIA-PACIFIC GENE THERAPY MARKET SIZE, BY VECTOR TYPE, 2018-2032 (USD MILLION)
  • TABLE 246. ASIA-PACIFIC GENE THERAPY MARKET SIZE, BY NON-VIRAL VECTORS, 2018-2032 (USD MILLION)
  • TABLE 247. ASIA-PACIFIC GENE THERAPY MARKET SIZE, BY VIRAL VECTORS, 2018-2032 (USD MILLION)
  • TABLE 248. ASIA-PACIFIC GENE THERAPY MARKET SIZE, BY TREATMENT MODALITY, 2018-2032 (USD MILLION)
  • TABLE 249. ASIA-PACIFIC GENE THERAPY MARKET SIZE, BY SOMATIC CELL THERAPY, 2018-2032 (USD MILLION)
  • TABLE 250. ASIA-PACIFIC GENE THERAPY MARKET SIZE, BY TARGET GENOME, 2018-2032 (USD MILLION)
  • TABLE 251. ASIA-PACIFIC GENE THERAPY MARKET SIZE, BY DELIVERY MODE, 2018-2032 (USD MILLION)
  • TABLE 252. ASIA-PACIFIC GENE THERAPY MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 253. ASIA-PACIFIC GENE THERAPY MARKET SIZE, BY PATIENT TYPE, 2018-2032 (USD MILLION)
  • TABLE 254. ASIA-PACIFIC GENE THERAPY MARKET SIZE, BY THERAPEUTIC AREA, 2018-2032 (USD MILLION)
  • TABLE 255. ASIA-PACIFIC GENE THERAPY MARKET SIZE, BY CARDIOVASCULAR DISEASES, 2018-2032 (USD MILLION)
  • TABLE 256. ASIA-PACIFIC GENE THERAPY MARKET SIZE, BY INFECTIOUS DISEASES, 2018-2032 (USD MILLION)
  • TABLE 257. ASIA-PACIFIC GENE THERAPY MARKET SIZE, BY MONOGENIC DISORDERS, 2018-2032 (USD MILLION)
  • TABLE 258. ASIA-PACIFIC GENE THERAPY MARKET SIZE, BY ONCOLOGICAL DISORDERS, 2018-2032 (USD MILLION)
  • TABLE 259. ASIA-PACIFIC GENE THERAPY MARKET SIZE, BY END-USER, 2018-2032 (USD MILLION)
  • TABLE 260. GLOBAL GENE THERAPY MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 261. ASEAN GENE THERAPY MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 262. ASEAN GENE THERAPY MARKET SIZE, BY VECTOR TYPE, 2018-2032 (USD MILLION)
  • TABLE 263. ASEAN GENE THERAPY MARKET SIZE, BY NON-VIRAL VECTORS, 2018-2032 (USD MILLION)
  • TABLE 264. ASEAN GENE THERAPY MARKET SIZE, BY VIRAL VECTORS, 2018-2032 (USD MILLION)
  • TABLE 265. ASEAN GENE THERAPY MARKET SIZE, BY TREATMENT MODALITY, 2018-2032 (USD MILLION)
  • TABLE 266. ASEAN GENE THERAPY MARKET SIZE, BY SOMATIC CELL THERAPY, 2018-2032 (USD MILLION)
  • TABLE 267. ASEAN GENE THERAPY MARKET SIZE, BY TARGET GENOME, 2018-2032 (USD MILLION)
  • TABLE 268. ASEAN GENE THERAPY MARKET SIZE, BY DELIVERY MODE, 2018-2032 (USD MILLION)
  • TABLE 269. ASEAN GENE THERAPY MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 270. ASEAN GENE THERAPY MARKET SIZE, BY PATIENT TYPE, 2018-2032 (USD MILLION)
  • TABLE 271. ASEAN GENE THERAPY MARKET SIZE, BY THERAPEUTIC AREA, 2018-2032 (USD MILLION)
  • TABLE 272. ASEAN GENE THERAPY MARKET SIZE, BY CARDIOVASCULAR DISEASES, 2018-2032 (USD MILLION)
  • TABLE 273. ASEAN GENE THERAPY MARKET SIZE, BY INFECTIOUS DISEASES, 2018-2032 (USD MILLION)
  • TABLE 274. ASEAN GENE THERAPY MARKET SIZE, BY MONOGENIC DISORDERS, 2018-2032 (USD MILLION)
  • TABLE 275. ASEAN GENE THERAPY MARKET SIZE, BY ONCOLOGICAL DISORDERS, 2018-2032 (USD MILLION)
  • TABLE 276. ASEAN GENE THERAPY MARKET SIZE, BY END-USER, 2018-2032 (USD MILLION)
  • TABLE 277. GCC GENE THERAPY MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 278. GCC GENE THERAPY MARKET SIZE, BY VECTOR TYPE, 2018-2032 (USD MILLION)
  • TABLE 279. GCC GENE THERAPY MARKET SIZE, BY NON-VIRAL VECTORS, 2018-2032 (USD MILLION)
  • TABLE 280. GCC GENE THERAPY MARKET SIZE, BY VIRAL VECTORS, 2018-2032 (USD MILLION)
  • TABLE 281. GCC GENE THERAPY MARKET SIZE, BY TREATMENT MODALITY, 2018-2032 (USD MILLION)
  • TABLE 282. GCC GENE THERAPY MARKET SIZE, BY SOMATIC CELL THERAPY, 2018-2032 (USD MILLION)
  • TABLE 283. GCC GENE THERAPY MARKET SIZE, BY TARGET GENOME, 2018-2032 (USD MILLION)
  • TABLE 284. GCC GENE THERAPY MARKET SIZE, BY DELIVERY MODE, 2018-2032 (USD MILLION)
  • TABLE 285. GCC GENE THERAPY MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 286. GCC GENE THERAPY MARKET SIZE, BY PATIENT TYPE, 2018-2032 (USD MILLION)
  • TABLE 287. GCC GENE THERAPY MARKET SIZE, BY THERAPEUTIC AREA, 2018-2032 (USD MILLION)
  • TABLE 288. GCC GENE THERAPY MARKET SIZE, BY CARDIOVASCULAR DISEASES, 2018-2032 (USD MILLION)
  • TABLE 289. GCC GENE THERAPY MARKET SIZE, BY INFECTIOUS DISEASES, 2018-2032 (USD MILLION)
  • TABLE 290. GCC GENE THERAPY MARKET SIZE, BY MONOGENIC DISORDERS, 2018-2032 (USD MILLION)
  • TABLE 291. GCC GENE THERAPY MARKET SIZE, BY ONCOLOGICAL DISORDERS, 2018-2032 (USD MILLION)
  • TABLE 292. GCC GENE THERAPY MARKET SIZE, BY END-USER, 2018-2032 (USD MILLION)
  • TABLE 293. EUROPEAN UNION GENE THERAPY MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 294. EUROPEAN UNION GENE THERAPY MARKET SIZE, BY VECTOR TYPE, 2018-2032 (USD MILLION)
  • TABLE 295. EUROPEAN UNION GENE THERAPY MARKET SIZE, BY NON-VIRAL VECTORS, 2018-2032 (USD MILLION)
  • TABLE 296. EUROPEAN UNION GENE THERAPY MARKET SIZE, BY VIRAL VECTORS, 2018-2032 (USD MILLION)
  • TABLE 297. EUROPEAN UNION GENE THERAPY MARKET SIZE, BY TREATMENT MODALITY, 2018-2032 (USD MILLION)
  • TABLE 298. EUROPEAN UNION GENE THERAPY MARKET SIZE, BY SOMATIC CELL THERAPY, 2018-2032 (USD MILLION)
  • TABLE 299. EUROPEAN UNION GENE THERAPY MARKET SIZE, BY TARGET GENOME, 2018-2032 (USD MILLION)
  • TABLE 300. EUROPEAN UNION GENE THERAPY MARKET SIZE, BY DELIVERY MODE, 2018-2032 (USD MILLION)
  • TABLE 301. EUROPEAN UNION GENE THERAPY MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 302. EUROPEAN UNION GENE THERAPY MARKET SIZE, BY PATIENT TYPE, 2018-2032 (USD MILLION)
  • TABLE 303. EUROPEAN UNION GENE THERAPY MARKET SIZE, BY THERAPEUTIC AREA, 2018-2032 (USD MILLION)
  • TABLE 304. EUROPEAN UNION GENE THERAPY MARKET SIZE, BY CARDIOVASCULAR DISEASES, 2018-2032 (USD MILLION)
  • TABLE 305. EUROPEAN UNION GENE THERAPY MARKET SIZE, BY INFECTIOUS DISEASES, 2018-2032 (USD MILLION)
  • TABLE 306. EUROPEAN UNION GENE THERAPY MARKET SIZE, BY MONOGENIC DISORDERS, 2018-2032 (USD MILLION)
  • TABLE 307. EUROPEAN UNION GENE THERAPY MARKET SIZE, BY ONCOLOGICAL DISORDERS, 2018-2032 (USD MILLION)
  • TABLE 308. EUROPEAN UNION GENE THERAPY MARKET SIZE, BY END-USER, 2018-2032 (USD MILLION)
  • TABLE 309. BRICS GENE THERAPY MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 310. BRICS GENE THERAPY MARKET SIZE, BY VECTOR TYPE, 2018-2032 (USD MILLION)
  • TABLE 311. BRICS GENE THERAPY MARKET SIZE, BY NON-VIRAL VECTORS, 2018-2032 (USD MILLION)
  • TABLE 312. BRICS GENE THERAPY MARKET SIZE, BY VIRAL VECTORS, 2018-2032 (USD MILLION)
  • TABLE 313. BRICS GENE THERAPY MARKET SIZE, BY TREATMENT MODALITY, 2018-2032 (USD MILLION)
  • TABLE 314. BRICS GENE THERAPY MARKET SIZE, BY SOMATIC CELL THERAPY, 2018-2032 (USD MILLION)
  • TABLE 315. BRICS GENE THERAPY MARKET SIZE, BY TARGET GENOME, 2018-2032 (USD MILLION)
  • TABLE 316. BRICS GENE THERAPY MARKET SIZE, BY DELIVERY MODE, 2018-2032 (USD MILLION)
  • TABLE 317. BRICS GENE THERAPY MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 318. BRICS GENE THERAPY MARKET SIZE, BY PATIENT TYPE, 2018-2032 (USD MILLION)
  • TABLE 319. BRICS GENE THERAPY MARKET SIZE, BY THERAPEUTIC AREA, 2018-2032 (USD MILLION)
  • TABLE 320. BRICS GENE THERAPY MARKET SIZE, BY CARDIOVASCULAR DISEASES, 2018-2032 (USD MILLION)
  • TABLE 321. BRICS GENE THERAPY MARKET SIZE, BY INFECTIOUS DISEASES, 2018-2032 (USD MILLION)
  • TABLE 322. BRICS GENE THERAPY MARKET SIZE, BY MONOGENIC DISORDERS, 2018-2032 (USD MILLION)
  • TABLE 323. BRICS GENE THERAPY MARKET SIZE, BY ONCOLOGICAL DISORDERS, 2018-2032 (USD MILLION)
  • TABLE 324. BRICS GENE THERAPY MARKET SIZE, BY END-USER, 2018-2032 (USD MILLION)
  • TABLE 325. G7 GENE THERAPY MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 326. G7 GENE THERAPY MARKET SIZE, BY VECTOR TYPE, 2018-2032 (USD MILLION)
  • TABLE 327. G7 GENE THERAPY MARKET SIZE, BY NON-VIRAL VECTORS, 2018-2032 (USD MILLION)
  • TABLE 328. G7 GENE THERAPY MARKET SIZE, BY VIRAL VECTORS, 2018-2032 (USD MILLION)
  • TABLE 329. G7 GENE THERAPY MARKET SIZE, BY TREATMENT MODALITY, 2018-2032 (USD MILLION)
  • TABLE 330. G7 GENE THERAPY MARKET SIZE, BY SOMATIC CELL THERAPY, 2018-2032 (USD MILLION)
  • TABLE 331. G7 GENE THERAPY MARKET SIZE, BY TARGET GENOME, 2018-2032 (USD MILLION)
  • TABLE 332. G7 GENE THERAPY MARKET SIZE, BY DELIVERY MODE, 2018-2032 (USD MILLION)
  • TABLE 333. G7 GENE THERAPY MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 334. G7 GENE THERAPY MARKET SIZE, BY PATIENT TYPE, 2018-2032 (USD MILLION)
  • TABLE 335. G7 GENE THERAPY MARKET SIZE, BY THERAPEUTIC AREA, 2018-2032 (USD MILLION)
  • TABLE 336. G7 GENE THERAPY MARKET SIZE, BY CARDIOVASCULAR DISEASES, 2018-2032 (USD MILLION)
  • TABLE 337. G7 GENE THERAPY MARKET SIZE, BY INFECTIOUS DISEASES, 2018-2032 (USD MILLION)
  • TABLE 338. G7 GENE THERAPY MARKET SIZE, BY MONOGENIC DISORDERS, 2018-2032 (USD MILLION)
  • TABLE 339. G7 GENE THERAPY MARKET SIZE, BY ONCOLOGICAL DISORDERS, 2018-2032 (USD MILLION)
  • TABLE 340. G7 GENE THERAPY MARKET SIZE, BY END-USER, 2018-2032 (USD MILLION)
  • TABLE 341. NATO GENE THERAPY MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 342. NATO GENE THERAPY MARKET SIZE, BY VECTOR TYPE, 2018-2032 (USD MILLION)
  • TABLE 343. NATO GENE THERAPY MARKET SIZE, BY NON-VIRAL VECTORS, 2018-2032 (USD MILLION)
  • TABLE 344. NATO GENE THERAPY MARKET SIZE, BY VIRAL VECTORS, 2018-2032 (USD MILLION)
  • TABLE 345. NATO GENE THERAPY MARKET SIZE, BY TREATMENT MODALITY, 2018-2032 (USD MILLION)
  • TABLE 346. NATO GENE THERAPY MARKET SIZE, BY SOMA